The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment

被引:3
|
作者
Maiden, Martin Christopher James [1 ]
机构
[1] Univ Oxford, Dept Zool, Oxford, England
来源
FRONTIERS IN IMMUNOLOGY | 2019年 / 9卷
基金
美国国家卫生研究院; 英国惠康基金;
关键词
Neisseria meningitidis; conjugate polysaccharide vaccines; outer membrane vesicle vaccines; population biology; herd immunity; efficacy; OUTER-MEMBRANE PROTEIN; HORIZONTAL GENETIC EXCHANGE; AFRICAN MENINGITIS BELT; NEISSERIA-MENINGITIDIS; SEROGROUP-B; CONJUGATE VACCINE; STRAIN COVERAGE; CARRIAGE; DISEASE; POPULATION;
D O I
10.3389/fimmu.2018.03151
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since it became available as a routine tool in biology, the determination and analysis of nucleotide sequences has been applied to the design of vaccines and the investigation of their effectiveness. As vaccination is primarily concerned with the interaction of biological molecules with the immune system, the utility of sequence data is not immediately obvious and, indeed, nucleotide sequence data are most effective when used to complement more conventional immunological approaches. Here, the impact of sequencing on the field of vaccinology will be illustrated with reference to the development and implementation of vaccines against Neisseria meningitidis (the meningococcus) over the 30-year period from the late-1980s to the late-2010s. Nucleotide sequence-based studies have been important in the fight against this aggressive pathogen largely because of its high genetic and antigenic diversity, properties that were only fully appreciated because of sequence-based studies. Five aspects will be considered, the use of sequence data to: (i) discover vaccine antigens; (ii) assess the diversity and distribution of vaccine antigens; (iii) determine the evolutionary and population biology of the organism and their implications for immunization; and (iv) develop molecular approaches to investigate pre- and post-vaccine pathogen populations to assess vaccine impact. One of the great advantages of nucleotide sequence data has been its scalability, which has meant that increasingly large data sets have been available, which has proved invaluable in the investigation of an organism as diverse and enigmatic as the meningococcus.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series
    de Waure, Chiara
    Miglietta, Alessandro
    Nedovic, Darko
    Mereu, Giovanna
    Ricciardi, Walter
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (02) : 467 - 473
  • [22] Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents
    McMillan, Mark
    Wang, Bing
    Koehler, Ann P.
    Sullivan, Thomas R.
    Marshall, Helen S.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : E233 - E237
  • [23] Challenges and progress in the development of a serogroup B meningococcal vaccine
    Lewis, Susan
    Sadarangani, Manish
    Hoe, J. Claire
    Pollard, Andrew J.
    EXPERT REVIEW OF VACCINES, 2009, 8 (06) : 729 - 745
  • [24] Global practices of meningococcal vaccine use and impact on invasive disease
    Ali, Asad
    Jafri, Rabab Zehra
    Messonnier, Nancy
    Tevi-Benissan, Carol
    Durrheim, David
    Eskola, Juhani
    Fermon, Florence
    Klugman, Keith P.
    Ramsay, Mary
    Sow, Samba
    Shao Zhujun
    Bhutta, Zulfiqar
    Abramson, Jon
    PATHOGENS AND GLOBAL HEALTH, 2014, 108 (01) : 11 - 20
  • [25] Impact of serogroup A meningococcal conjugate vaccine for Africa
    Stuart, James M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (05) : 1116 - 1117
  • [26] Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine
    Lucidarme, Jay
    Comanducci, Maurizio
    Findlow, Jamie
    Gray, Stephen J.
    Kaczmarski, Edward B.
    Guiver, Malcolm
    Vallely, Pamela J.
    Oster, Philipp
    Pizza, Mariagrazia
    Bambini, Stefania
    Muzzi, Alessandro
    Borrow, Ray
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (06) : 919 - 929
  • [27] Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis
    Bettinger, Julie A.
    Scheifele, David W.
    Halperin, Scott A.
    Kellner, James D.
    Vanderkooi, Otto G.
    Schryvers, Anthony
    De Serres, Gaston
    Alcantara, Joenel
    VACCINE, 2012, 30 (27) : 4023 - 4027
  • [28] Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens
    Jacobsson, S
    Thulin, S
    Mölling, P
    Unemo, M
    Comanducci, M
    Rappuoli, R
    Olcén, P
    VACCINE, 2006, 24 (12) : 2161 - 2168
  • [29] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    O'Ryan, Miguel
    Stoddard, Jeffrey
    Toneatto, Daniela
    Wassil, James
    Dull, Peter M.
    DRUGS, 2014, 74 (01) : 15 - 30
  • [30] Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction
    Martinelli, Domenico
    Fortunato, Francesca
    Cappelli, Maria Giovanna
    Cozza, Vanessa
    Chironna, Maria
    Prato, Rosa
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015